MONALEESA-2 · 2016 · New England Journal of Medicine
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Adding ribociclib to letrozole improves progression-free survival in HR+/HER2− advanced breast cancer.
Source publication
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi et al. · New England Journal of Medicine · 2016
Sponsor
Novartis Pharmaceuticals
Principal investigator
Novartis Pharmaceuticals
Population
Advanced, Metastatic Breast Cancer; n=668
Primary endpoint
Progression Free Survival (PFS) by Investigator Assessment
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$2.5M / $4.1M
62%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1